KIT and neoplasm: Indeed, assuming that patients with any PDGFRA mutation show a more favorable natural history when compared to those with KIT mutations, Vitiello and colleagues hypothesized that the mutational driver may impact other aspects of tumor biology, specifically, the tumor microenvironment and host immune response (Figure 2).